相似文献
1
Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
Oncologist. 2010;15(7):683-94. doi: 10.1634/theoncologist.2009-0235. Epub 2010 Jun 14.
2
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
Oncologist. 2010;15(2):130-41. doi: 10.1634/theoncologist.2009-0252. Epub 2010 Feb 5.
3
Adverse effects of anticancer agents that target the VEGF pathway.
Nat Rev Clin Oncol. 2009 Aug;6(8):465-77. doi: 10.1038/nrclinonc.2009.94. Epub 2009 Jul 7.
4
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
Br J Cancer. 2007 Jun 18;96(12):1788-95. doi: 10.1038/sj.bjc.6603813. Epub 2007 May 22.
5
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
Lancet Oncol. 2010 Apr;11(4):373-82. doi: 10.1016/S1470-2045(09)70341-9. Epub 2010 Feb 18.
6
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
Ann Oncol. 2009 May;20(5):966-7; author reply 967. doi: 10.1093/annonc/mdp201.
7
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
Target Oncol. 2009 Apr;4(2):67-76. doi: 10.1007/s11523-009-0106-0. Epub 2009 Apr 17.
8
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Breast. 2011 Apr;20(2):176-83. doi: 10.1016/j.breast.2010.11.002. Epub 2010 Dec 13.
9
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
Clin Lung Cancer. 2006 Dec;8 Suppl 1:S23-30. doi: 10.3816/clc.2006.s.010.
10
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
Clin Cancer Res. 2009 Feb 15;15(4):1411-6. doi: 10.1158/1078-0432.CCR-08-1141.
引用本文的文献
1
Cardio-oncology: Emerging Concepts in Cardiovascular Sequelae of Cancer Therapies, Translational Research and Reverse Cardio-oncology.
Eur Cardiol. 2025 Mar 21;20:e05. doi: 10.15420/ecr.2024.49. eCollection 2025.
2
Causes of death among people living with metastatic cancer.
Nat Commun. 2024 Feb 19;15(1):1519. doi: 10.1038/s41467-024-45307-x.
3
Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system.
Cardiooncology. 2023 Sep 25;9(1):35. doi: 10.1186/s40959-023-00184-z.
4
Cardiovascular Complications of Pan-Cancer Therapies: The Need for Cardio-Oncology.
Cancers (Basel). 2023 Jun 5;15(11):3055. doi: 10.3390/cancers15113055.
5
Suicide and Cardiovascular Death Among Patients With Multiple Primary Cancers in the United States.
Front Cardiovasc Med. 2022 Jun 6;9:857194. doi: 10.3389/fcvm.2022.857194. eCollection 2022.
6
Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review.
Curr Cardiol Rev. 2023;19(3):e310522205428. doi: 10.2174/1573403X18666220531094800.
7
Atherosclerosis, Ischemia, and Anticancer Drugs.
Heart Views. 2021 Apr-Jun;22(2):127-133. doi: 10.4103/HEARTVIEWS.HEARTVIEWS_45_20. Epub 2021 Aug 19.
8
A population-based study of cardiovascular disease mortality risk in US cancer patients.
Eur Heart J. 2019 Dec 21;40(48):3889-3897. doi: 10.1093/eurheartj/ehz766.
9
Homocysteine inhibits the viability and migration ability of human umbilical vein endothelial cells by downregulating the expression of vascular endothelial growth factor.
Exp Ther Med. 2019 Nov;18(5):3913-3919. doi: 10.3892/etm.2019.8043. Epub 2019 Sep 25.
10
A database of tissue-specific rhythmically expressed human genes has potential applications in circadian medicine.
Sci Transl Med. 2018 Sep 12;10(458). doi: 10.1126/scitranslmed.aat8806.
本文引用的文献
1
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
J Clin Oncol. 2010 May 1;28(13):2280-5. doi: 10.1200/JCO.2009.27.2757. Epub 2010 Mar 29.
2
Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
Am J Hypertens. 2010 May;23(5):460-8. doi: 10.1038/ajh.2010.25. Epub 2010 Feb 25.
3
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
Acta Oncol. 2010 Apr;49(3):287-97. doi: 10.3109/02841860903524396.
4
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Cancer. 2010 Mar 1;116(5):1272-80. doi: 10.1002/cncr.24864.
5
Thrombotic events in patients with cancer receiving antiangiogenesis agents.
J Clin Oncol. 2009 Oct 10;27(29):4865-73. doi: 10.1200/JCO.2009.22.3875. Epub 2009 Aug 24.
6
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
Lancet Oncol. 2009 Aug;10(8):757-63. doi: 10.1016/S1470-2045(09)70162-7. Epub 2009 Jul 15.
7
Anti-angiogenic therapies for metastatic colorectal cancer.
Cochrane Database Syst Rev. 2009 Jul 8(3):CD005392. doi: 10.1002/14651858.CD005392.pub3.
8
Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.
J Am Coll Cardiol. 2009 Jun 16;53(24):2231-47. doi: 10.1016/j.jacc.2009.02.050.
9
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
J Clin Oncol. 2009 Jul 10;27(20):3385-90. doi: 10.1200/JCO.2009.21.9220. Epub 2009 May 4.
10
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Ann Oncol. 2009 Nov;20(11):1842-7. doi: 10.1093/annonc/mdp233. Epub 2009 Apr 30.
Zotero 插件